Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN421(SAR153192)
REGN421 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Q2W | EXPERIMENTAL | REGN421 (SAR153192) taken once every two weeks (Q2W) |
| Name | Type | Description |
|---|---|---|
| REGN421(SAR153192) | DRUG | - |
Inclusion Criteria: 1. Male or female 18 years of age or older 2. Histologically diagnosis of advanced solid malignancy, with no standard therapeutic options of proven benefit. 3. Patients with measurable or non-measurable disease 4. At least 6 weeks must have elapsed since the last dose of bevaciz...
REGN421 is an investigational small molecule being studied for the treatment of advanced solid malignancies. It has been evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. It is not approved for any indication and remains in clinical development.
REGN421 targets Delta-like ligand-4 (Dll4), a protein involved in tumor angiogenesis. By binding to Dll4, the drug aims to disrupt Notch signaling in the tumor vasculature. This mechanism is being explored as a potential anticancer strategy in advanced solid malignancies.
REGN421 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. The company is responsible for the clinical development of the compound, including the Phase 1 study in advanced solid malignancies.
REGN421 is in Phase 1 clinical development. It has completed one Phase 1 trial in patients with advanced solid malignancies. The drug is investigational and has not been approved by the FDA or any regulatory agency for commercial use.
REGN421 has been evaluated in a single Phase 1 trial, NCT00871559, titled A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies. The trial enrolled 83 patients in the United States and is now completed.
Yes, REGN421 is also known as SAR153192. The two names refer to the same investigational compound. REGN421(SAR153192) is the designation used in its Phase 1 clinical trial in advanced solid malignancies.